Psyence Biomedical Ltd (PBM) Return on Investment ROI from the second quarter of 2025 to second quarter of 2024 and for the year 2025, average high and low, overall ranking from Sep 30 2025 to 0 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Psyence Biomedical ltd   (NASDAQ: PBM)


Psyence Biomedical Ltd's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Psyence Biomedical Ltd's ROI in the second quarter of 2025?
Psyence Biomedical Ltd recorded a cumulative net loss of $-52 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -1045.8%.

Within the Healthcare sector 884 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2024 from to 4563.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2025)
II. Quarter		 (Mar 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter
Y / Y Investment Change TTM 33.68 % 508.81 % 385.91 % 1027.12 % -36.99 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 13 7 0 0 11
Return On Investment (TTM) -1045.8 % -1124.68 % -18.28 % - -27.04 %
PBM's Overall Ranking # 4563 # # # #
Seq. Investment Change TTM 9.13 % 50.67 % -6.75 % -12.82 % 397.01 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -52 -51 -1 -1 -1

PBM Company Profile >> Back to PBM Roi Comparisons >> See Annual PBM Return On Investment



Return On Investment PBM's Ranking
Within: No.
Industry # 439
Sector # 885
Overall # 4563

Return On Investment Statistics
High Average Low
-2.05 %
-796.48 %
-4518.72 %
(Jan 31 2021)   (Mar 31 2024)



  News about Psyence Biomedical ltd Return on Investment ROI

Psyence Biomed Charts New Growth Path with SEC-Approved $25 Million Equity Line from White Lion Capital,

August 30, 2024

Psyence Biomed Secures $25 Million Equity Line of Credit with White Lion Capital: A Strategic Move for Financial Stability and Growth Psyence Biomedical Ltd. a notable entity in the biotech sector, has announced a significant financial development following the U.S. Securities and Exchange Commission s (SEC) declaration of effectiveness concerning its registration statement on Form F-1. The effective registration allows Psyence Biomed to access an equity line of credit (ELOC) amounting up to $25 million through a strategic partnership with White Lion Capital, LLC. This arrangement is poised to bolster the company s operational flexibility and facilitate its ongoing commitment to advancing psychedelic therapies, particularly in mental health and wellness. Understanding the Equity Line of Credit Historically, an equity line of credit can serve as an essential financial tool for companies seeking to maintain stability while pursuing growth opportunities. The arrangement allows Psyence Biomed to sell shares to White Lion Capital over a 24-month period, enabling the company to raise capital as needed without necessarily taking on complex debt. The terms under which this capital can be accessed are subject to specific conditions, providing a safety net for both Psyence Biomed and investors.





Financial Statements
Psyence Biomedical Ltd's II. Quarter Investments $ 13 Millions PBM's Balance sheet
Psyence Biomedical Ltd's II. Quarter Income $ -1 Millions Quarterly PBM's Income Statement
PBM's Income by Division See PBM's Income by Division


PBM Annual Return On Investment (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Jan 31 2023)
2023		 (Jan 31 2022)
2022		 (Jan 31 2021)
2021
Total Investments in Millions 7 1 0 2 24
Y / Y Investment Growth 493.73 % - - -92.94 % -1.33 %
Net Income in Millions 1 -51 -3 -26 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment 15.05 % -4518.72 % - -1551.46 % -2.05 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 15.05 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PBM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PBM's Competitors
Subscribers only: Roi for Psyence Biomedical Ltd's Suppliers
Subscribers only: Return On Investment for PBM's Customers

Other Ratios
PBM's Roa PBM's Inventory Turnover Ratio PBM's Growth Rates PBM's Dividend Statistics
PBM's Profitability Ratios PBM's Asset Turnover Ratio PBM's Dividend Growth
PBM's Roe PBM's Valuation Ratios PBM's Financial Strength Ratios PBM's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-30T13:42:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.